Pfizer CEO: Vaccine achieved safety requirement in trials and will request authorization to begin manufacturing

Pfizer CEO Albert Bourla said a key safety milestone had been reached in the clinical trial of its vaccine against Covid-19.

In a conference organized Tuesday by the New York Times, Bourla said that the company was preparing to submit its data to the US Food and Drug Administration (FDA) for an emergency use authorization.

Last week, the company and its partner, BioNTech SE, reported that an interim analysis showed that their vaccine was more than 90% effective in preventing Covid-19.

“We are preparing for the presentations”Bourla said at the DealBook conference.

Bourla has said that the company can produce up to 50 million doses by the end of the year, and half of that supply will go to other countries. Because the vaccine requires two doses, there will initially be enough for only 12.5 million of the 330 million Americans.

Since then, the company has upgraded its production lines in the United States and Europe, Rose said, and is confident in its ability to supply around 1.3 billion doses by the end of next year.